With biosimilars to AstraZeneca’s blockbuster rare blood disease med Soliris recently available in the U.S., nonprofit health ...

AstraZeneca's new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

We recently published a list of 10 Best UK Stocks to Buy According to Billionaires. In this article, we are going to take a ...

Now may be an ideal time to buy stocks. Even if you don't have a lot of money that you can afford to invest, there are many ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Investors are nervous. As of 9:55 a.m. ET Wednesday morning, shares of Roche Holding ( RHHBY -2.81%) are down 2.3%, Eli Lilly ( LLY -4.38%) stock is off 3.2%, and AstraZeneca ( AZN -4.87%) is doing ...

The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing significant survival benefits.

March 21 (UPI) --AstraZeneca plans to build a $2.5 billion research and development center in Beijing, the Britain-based multinational pharmaceutical announced Friday. The investment will mark the ...

Step aside football, basketball and hockey, AstraZeneca is bringing its sports marketing efforts to the fastest-growing sport in America — pickleball. The pharma giant recently announced a partnership ...

AstraZeneca AZN-0.39%decrease; red down pointing triangle plans to invest $2.5 billion in China over five years to build a research-and-development center and strike deals with local biotechnology ...

(Bloomberg) -- AstraZeneca Plc will invest $2.5 billion in a new research center in Beijing, in a major show of commitment to China just months after the company’s top executive there was ...

LONDON (Reuters) - AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market ...